Baudax Bio Reports 2022 Fourth Quarter and Annual Financial Results and Provides Business Update

Feb 23, 2023 8:00am EST

Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000

Jan 24, 2023 8:00am EST

Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery

Dec 08, 2022 8:00am EST

Baudax Bio Announces Closing of $5 Million Public Offering

Dec 06, 2022 4:11pm EST

Baudax Bio Announces Pricing of $5 Million Public Offering

Dec 02, 2022 2:46pm EST

Baudax Bio Announces 1-for-40 Reverse Stock Split

Nov 30, 2022 4:50pm EST

Baudax Bio Reports Third Quarter 2022 Financial Results and Business Highlights

Nov 08, 2022 4:09pm EST

Baudax Bio Announces Distribution of Series B Preferred Stock to Holders of its Common Stock

Sep 19, 2022 4:05pm EDT

Baudax Bio to Present at the 24th Annual H.C. Wainwright Healthcare Conference

Sep 08, 2022 4:05pm EDT

Baudax Bio Announces Closing of $6.2 Million Public Offering

Sep 01, 2022 2:56pm EDT